WFH/X
Aug 21, 2025, 14:49
Beyond Factor Therapy: Marstacimab for Hemophilia Care
World Federation of Hemophilia (WFH) shared a post on X:
“Beyond factor therapy: Marstacimab targets TFPI to restore thrombin generation, offering an easier, effective prophylaxis for hemophilia A and B. Strong efficacy and safety in trials. Explore the data.”
Title: Marstacimab for the Treatment of Hemophilia A or B
Author: Johnny Mahlangu
Stay updated with Hemostasis Today.
-
Jan 14, 2026, 05:56Arun V J on The “Whole Blood” Nostalgia Trap
-
Jan 13, 2026, 16:38Caitlin Raymond: Understanding TAMOF as a TTP-Like Process
-
Jan 13, 2026, 15:22John Amako: Childhood to Adulthood Management Approach for SCD
-
Jan 13, 2026, 13:03Claudio Laudani on Dual Versus Single Antiplatelet Therapy
-
Jan 13, 2026, 12:46Stephanie Carlin and Colleagues on Clinical Outcomes of DOAC-Anticonvulsant Coprescription
-
Jan 13, 2026, 10:53Lena Volland on Ming Y Lim’s Example of Designing Care Models for WGBD Community With Intention
-
Jan 13, 2026, 05:05Pablo Corral Shares Key Takeaways on Reducing LDL-Cholesterol to Very Low Levels
-
Jan 13, 2026, 04:49Martin Haluzík Shares A Study on GLP1-1RAs Use in Peripheral Artery Disease and DM
-
Jan 13, 2026, 04:37Shreya Agarwal and Bryce A Kerlin on The Impact of Advanced Hemostasis and Thrombosis Fellowship Trainings